Gentle movement during cancer treatment can help maintain strength, mobility and balance. Follow Jennifer Tipton’s simple exercises to keep your body moving.
|Articles|February 9, 2022
Upcoming Advocacy Chat: What is High Quality Cancer Care?
Listen
0:00 / 0:00
Key Takeaways
- Stakeholders differ on what constitutes “high quality” oncology care and who sets the standard.
- Community practices must translate quality concepts into measurable processes, documentation, and consistent clinical pathways.
Physicians and patients agree: cancer care should be effective and high quality.
Advertisement
Physicians and patients agree: cancer care should be effective and high quality. What does high quality mean though, and who is defining it? How does a community oncology practice achieve the goal of providing high quality care? Once a practice reaches the standard of “high quality,” how does it maintain that standard? These are the questions that keep practice improvement experts, like Bo Gamble, busy, and audience members will explore the answers to these questions during the March 2022 CPAN Advocacy Chat
When: March 9th, 2022, 12:00-12:30pm ET
Click here to register
Advertisement
Related to this article
At three years, 69% of patients treated with Imfinzi and chemotherapy around surgery were alive, compared with 62% of patients treated with chemotherapy alone.
Hannah was 11 when she was diagnosed with acute lymphoblastic leukemia (ALL). Four years, two relapses and a 53-day hospital stay later, she is back in school.
A reflection on shame, vulnerability and transformation, exploring how the past shapes us and how presence can help us let go and heal.
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
AJ Wyman shares his daughter’s cancer journey and why parents caring for a child with cancer must make time for their own mental health, too.
A powerful reflection on finding hope, healing and meaning through life’s challenges, inspired by the lessons and beauty found in the sea.
In the phase 3 DESTINY-Lung04 trial, patients with HER2-mutant advanced non-small cell lung cancer treated with Enhertu went a median of 14.3 months without their disease worsening, compared with 8.3 months with immunotherapy plus chemotherapy.
Advertisement
Advertisement